These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 38272564)

  • 1. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer.
    Gu C; Wang X; Wang K; Xie F; Chen L; Ji H; Sun J
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 4. Combining local cryoablation with PD-L1 blockade synergistically eradicates established murine lung cancer by modulating mitochondrial in PD-1+CD8+ T cell.
    Zhai JW; Lv LL; Wu JJ; Zhang YX; Shen Y; Qu QX; Chen C
    Immunol Lett; 2023 Nov; 263():61-69. PubMed ID: 37805094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 9. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation.
    Alshebremi M; Tomchuck SL; Myers JT; Kingsley DT; Eid S; Abiff M; Bonner M; Saab ST; Choi SH; Huang AY
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity.
    Salehi-Rad R; Lim RJ; Du Y; Tran LM; Li R; Ong SL; Ling Huang Z; Dumitras C; Zhang T; Park SJ; Crosson W; Kahangi B; Abascal J; Seet C; Oh M; Shabihkhani M; Paul M; Krysan K; Lisberg AE; Garon EB; Liu B; Dubinett SM
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer.
    Lao J; Cao C; Niu X; Deng S; Ming S; Liang S; Shang Y; Yuan Y; Shi X; Liang Z; Wu M; Wu Y
    Int Immunopharmacol; 2022 Jul; 108():108813. PubMed ID: 35580452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3.
    Ao YQ; Gao J; Jin C; Wang S; Zhang LC; Deng J; Chen ZW; Wang HK; Jiang JH; Ding JY
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38148115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.
    Kaneko K; Acharya CR; Nagata H; Yang X; Hartman ZC; Hobeika A; Hughes PF; Haystead TAJ; Morse MA; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in
    Adeegbe DO; Liu S; Hattersley MM; Bowden M; Zhou CW; Li S; Vlahos R; Grondine M; Dolgalev I; Ivanova EV; Quinn MM; Gao P; Hammerman PS; Bradner JE; Diehl JA; Rustgi AK; Bass AJ; Tsirigos A; Freeman GJ; Chen H; Wong KK
    Cancer Immunol Res; 2018 Oct; 6(10):1234-1245. PubMed ID: 30087114
    [No Abstract]   [Full Text] [Related]  

  • 16. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy.
    Wang H; Xia L; Yao CC; Dong H; Yang Y; Li C; Ji WX; Sun RM; Duan HQ; Mengzhou W; Xia WM; Wang SJ; Ji P; Li Z; Jiao L; Wang Y; Lu S
    Cancer Sci; 2022 Mar; 113(3):838-851. PubMed ID: 34927309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
    Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
    J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
    Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
    J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.
    Hwang M; Canzoniero JV; Rosner S; Zhang G; White JR; Belcaid Z; Cherry C; Balan A; Pereira G; Curry A; Niknafs N; Zhang J; Smith KN; Sivapalan L; Chaft JE; Reuss JE; Marrone K; Murray JC; Li QK; Lam V; Levy BP; Hann C; Velculescu VE; Brahmer JR; Forde PM; Seiwert T; Anagnostou V
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.